RAPT Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über RAPT Therapeutics Inc Unternehmen

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

RAPT Therapeutics Inc Informationen



BörsenkürzelRAPT

Name des UnternehmensRAPT Therapeutics Inc

IPO-datumOct 31, 2019

CEOWong (Brian)

Anzahl der mitarbeiter68

WertpapierartOrdinary Share

GeschäftsjahresendeOct 31

Addresse561 Eccles Ave

StadtSOUTH SAN FRANCISCO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94080

Telefon16504899000

Websitehttps://rapt.com/

BörsenkürzelRAPT

IPO-datumOct 31, 2019

CEOWong (Brian)

Führungskräfte von RAPT Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

--

Mr. Rodney K. B. Young

Chief Financial Officer

--

Dr. Mary Ann Gray, Ph.D.

Independent Director

--

-100.00%

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

--

Dr. Michael F. Giordano, M.D.

Independent Director

--

-100.00%

Ms. Linda Kozick

Independent Director

--

-100.00%

Ms. Lori Lyons-Williams

Independent Chairman of the Board

--

-100.00%

Dr. Scott N. Braunstein, M.D.

Independent Director

--

Dr. Ashley Dombkowski, Ph.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

--

Mr. Rodney K. B. Young

Chief Financial Officer

--

Dr. Mary Ann Gray, Ph.D.

Independent Director

--

-100.00%

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

--

Dr. Michael F. Giordano, M.D.

Independent Director

--

-100.00%

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, Feb 19

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Medicxi Ventures (UK) LLP

9.65%

TCG Crossover Management, LLC

8.92%

Forbion Capital Partners

6.33%

OrbiMed Advisors, LLC

5.67%

RTW Investments L.P.

5.65%

Andere

63.78%

Aktionäre

Anteil

Medicxi Ventures (UK) LLP

9.65%

TCG Crossover Management, LLC

8.92%

Forbion Capital Partners

6.33%

OrbiMed Advisors, LLC

5.67%

RTW Investments L.P.

5.65%

Andere

63.78%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

32.03%

Investment Advisor

26.01%

Private Equity

17.32%

Investment Advisor/Hedge Fund

17.05%

Venture Capital

16.62%

Research Firm

1.62%

Individual Investor

0.24%

Pension Fund

0.07%

Bank and Trust

0.06%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

290

18.77M

64.82%

+126.40K

2025Q3

290

16.78M

61.62%

-1.23M

2025Q2

295

16.40M

99.19%

-1.13M

2025Q1

309

29.14M

109.47%

+11.54M

2024Q4

309

140.52M

106.54%

+100.36M

2024Q3

304

31.22M

87.82%

-13.95M

2024Q2

305

33.18M

93.85%

-9.52M

2024Q1

295

33.76M

95.60%

-5.47M

2023Q4

282

36.46M

106.02%

-3.53M

2023Q3

281

36.40M

105.98%

-3.26M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Medicxi Ventures (UK) LLP

2.79M

10.08%

--

Sep 30, 2025

TCG Crossover Management, LLC

1.64M

5.9%

--

Sep 30, 2025

Forbion Capital Partners

1.83M

6.62%

+1.49M

+432.58%

Oct 23, 2025

OrbiMed Advisors, LLC

1.09M

3.92%

-555.29K

-33.82%

Sep 30, 2025

RTW Investments L.P.

1.47M

5.31%

--

Sep 30, 2025

Foresite Capital Management, LLC

1.56M

5.64%

--

Sep 30, 2025

Invus Public Equities Advisors, LLC

580.47K

2.09%

+580.47K

--

Sep 30, 2025

The Vanguard Group, Inc.

696.19K

2.51%

-183.86K

-20.89%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

Invesco Dorsey Wright SmallCap Momentum ETF

0.56%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Schwab U.S. Broad Market ETF

0%

Blueprint Chesapeake Multi-Asset Trend ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

DFA Dimensional US Core Equity Market ETF

0%

iShares Russell 3000 ETF

0%

Pacer WealthShield ETF

0%

T Rowe Price Small-Mid Cap ETF

0%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil0.56%

Avantis US Small Cap Equity ETF

Anteil0.02%

Invesco RAFI US 1500 Small-Mid ETF

Anteil0.01%

Schwab U.S. Broad Market ETF

Anteil0%

Blueprint Chesapeake Multi-Asset Trend ETF

Anteil0%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil0%

DFA Dimensional US Core Equity Market ETF

Anteil0%

iShares Russell 3000 ETF

Anteil0%

Pacer WealthShield ETF

Anteil0%

T Rowe Price Small-Mid Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Jun 13, 2025

Merger

8→1

Datum

Ex-Dividendentag

Art

Verhältnis

Jun 13, 2025

Merger

8→1